InsiderSignal.AI

InsiderSignal.ai

CRSP - Crispr Therapeutics AG

Insider Sale by Prasad Raju (CFO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

Yesterday, Prasad Raju, serving as CFO at Crispr Therapeutics AG (CRSP), sold 9,869 shares at $48.26 per share, for a total transaction value of $476,278.00. Following this transaction, Prasad Raju now holds 13,023 shares of CRSP.

This sale represents a 43.00% decrease in Prasad Raju's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, March 16, 2026 and publicly disclosed via SEC Form 4 filing on Tuesday, March 17, 2026, 1 day after the trade was made.

Crispr Therapeutics AG operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Prasad Raju

CFO

Raju Prasad, Ph.D. is the Chief Financial Officer of CRISPR Therapeutics AG, a position he has held since March 14, 2023.[[1]](https://www.marketscreener.com/insider/RAJU-PRASAD-A1QUXA/)[[3]](https://crisprtx.com/about-us/leadership/dr-raju-prasad) In this role, he oversees the company's financial and accounting operations for the gene-editing biotechnology firm.[[1]](https://www.marketscreener.com/insider/RAJU-PRASAD-A1QUXA/)[[3]](https://crisprtx.com/about-us/leadership/dr-raju-prasad) Prior to joining CRISPR Therapeutics, Dr. Prasad served in various roles at William Blair & Company from 2014 to 2023, most recently as a Partner and senior biotechnology analyst since January 2021, where he covered small-, mid-, and large-cap biotech companies and led coverage in cell therapy, gene therapy, and gene editing.[[1]](https://www.marketscreener.com/insider/RAJU-PRASAD-A1QUXA/)[[3]](https://crisprtx.com/about-us/leadership/dr-raju-prasad) Earlier, he worked as a research associate at the University of North Carolina at Chapel Hill’s Gillings School of Global Public Health and as an independent consultant with the U.S. Environmental Protection Agency.[[1]](https://www.marketscreener.com/insider/RAJU-PRASAD-A1QUXA/)[[3]](https://crisprtx.com/about-us/leadership/dr-raju-prasad) He holds a B.A. in cell biology and neuroscience from Rutgers University, an M.S. in exercise physiology from the University of Delaware, and a Ph.D. in environmental sciences and engineering from the University of North Carolina at Chapel Hill.[[1]](https://www.marketscreener.com/insider/RAJU-PRASAD-A1QUXA/)[[3]](https://crisprtx.com/about-us/leadership/dr-raju-prasad) Dr. Prasad is also the author of *Building Breakthroughs: On the Frontier of Medical Innovation* and serves on the advisory board of Portal Innovations.[[3]](https://crisprtx.com/about-us/leadership/dr-raju-prasad) Recently, as a corporate insider, he executed share transactions on January 6, 2026, including purchases and sales under a Rule 10b5-1 trading plan.[[2]](https://www.ainvest.com/news/crispr-therapeutics-cfo-prasad-raju-buys-23361-shares-45-15-share-sells-18933-shares-2601/)[[4]](https://longbridge.com/en/news/271993192)

View full insider profile →

Trade Price

$48.26

Quantity

9,869

Total Value

$476,278.00

Shares Owned

13,023

Trade Date

Monday, March 16, 2026

1 days ago

SEC Filing Date

Tuesday, March 17, 2026

Filed 1 day after trade

HEALTHCAREBIOTECHNOLOGY

About Crispr Therapeutics AG

Company Overview

No company information available
View news mentioning CRSP

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4869053

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime